GlassScriptPhysician profile
Arely Martinez
NPI 1770058711
$2,629.11
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $659 · 2022: $1,187 · 2023: $663 · 2024: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $465.95 | 2021-2023 | Nexletol |
| Lilly USA, LLC | $465.63 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $412.28 | 2021-2023 | Farxiga |
| Novo Nordisk INC | $324.83 | 2021-2023 | Ozempic, Rybelsus |
| Redhill Biopharma INC. | $194.52 | 2021-2022 | |
| Abbvie INC. | $192.67 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.09 | 2022-2023 | |
| Amarin Pharma, INC. | $82.84 | 2021-2022 | |
| Glaxosmithkline, LLC. | $69.55 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Genentech USA, INC. | $42.27 | 2021 | |
| Amgen INC. | $40.03 | 2021-2023 | Otezla, Repatha |
| Ironwood Pharmaceuticals, INC | $39.14 | 2023 | Linzess |
| Sanofi-Aventis U.S. LLC | $35.22 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.16 | 2022 | |
| Abbott Laboratories | $24.98 | 2023 | Freestyle Libre 3 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.31 | 2024 | Exalt Model D |
| Novartis Pharmaceuticals Corporation | $20.41 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arely Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.